Nationwide Fund Advisors Buys 50,431 Shares of LeMaitre Vascular, Inc. (LMAT)

Nationwide Fund Advisors lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 71.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 120,793 shares of the medical instruments supplier’s stock after buying an additional 50,431 shares during the period. Nationwide Fund Advisors owned approximately 0.63% of LeMaitre Vascular worth $4,520,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of LMAT. Vanguard Group Inc. boosted its stake in shares of LeMaitre Vascular by 6.5% in the first quarter. Vanguard Group Inc. now owns 660,331 shares of the medical instruments supplier’s stock valued at $16,264,000 after buying an additional 40,448 shares during the period. Geode Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 7.0% in the first quarter. Geode Capital Management LLC now owns 107,649 shares of the medical instruments supplier’s stock valued at $2,651,000 after buying an additional 7,023 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of LeMaitre Vascular by 38.8% in the first quarter. Goldman Sachs Group Inc. now owns 18,966 shares of the medical instruments supplier’s stock valued at $467,000 after buying an additional 5,299 shares during the period. Capstone Asset Management Co. bought a new stake in LeMaitre Vascular during the second quarter worth $243,000. Finally, Russell Investments Group Ltd. lifted its stake in LeMaitre Vascular by 5.6% during the second quarter. Russell Investments Group Ltd. now owns 158,761 shares of the medical instruments supplier’s stock worth $4,956,000 after purchasing an additional 8,348 shares during the last quarter. Institutional investors and hedge funds own 69.28% of the company’s stock.

Several equities research analysts have weighed in on LMAT shares. BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating on shares of LeMaitre Vascular in a research note on Sunday, October 29th. Canaccord Genuity restated a “hold” rating and set a $30.00 target price on shares of LeMaitre Vascular in a research note on Monday, October 9th. Benchmark cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, First Analysis cut LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price for the company. in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $32.20.

In other news, insider David B. Roberts sold 4,123 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $32.14, for a total value of $132,513.22. Following the completion of the transaction, the insider now directly owns 24,482 shares in the company, valued at approximately $786,851.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.70% of the stock is currently owned by corporate insiders.

LeMaitre Vascular, Inc. (NASDAQ LMAT) opened at $32.21 on Friday. LeMaitre Vascular, Inc. has a 12 month low of $19.82 and a 12 month high of $39.88. The company has a market capitalization of $629.39, a price-to-earnings ratio of 42.43, a PEG ratio of 2.59 and a beta of 0.55.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The company had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. During the same period in the prior year, the company earned $0.17 EPS. LeMaitre Vascular’s revenue was up 6.9% compared to the same quarter last year. equities analysts expect that LeMaitre Vascular, Inc. will post 0.84 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 7th. Stockholders of record on Wednesday, November 22nd were paid a $0.055 dividend. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, November 21st. LeMaitre Vascular’s payout ratio is 28.57%.

TRADEMARK VIOLATION NOTICE: “Nationwide Fund Advisors Buys 50,431 Shares of LeMaitre Vascular, Inc. (LMAT)” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/15/nationwide-fund-advisors-buys-50431-shares-of-lemaitre-vascular-inc-lmat.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

What are top analysts saying about LeMaitre Vascular? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LeMaitre Vascular and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit